期刊
TRENDS IN MOLECULAR MEDICINE
卷 26, 期 9, 页码 848-861出版社
CELL PRESS
DOI: 10.1016/j.molmed.2020.05.002
关键词
-
资金
- project `Acoes Integradas Luso-Francesas' [TC-15/17]
- `Cooperacao Cientifica e Tecnologica FCT/Acordo Pessoa' project [5079]
- FCT - Fundo Social Europeu [IF/00959/2015]
- Programa Operacional Potencial Humano
- FCT [UID/Multi/04349/2013]
- MIT Portugal project BIODEVICE [MIT-EXPL/BIO/0008/2017]
- UTAustin FCT project DREAM [UTAP-EXPL/NTec/0015/2017]
- Foundation for Science and Technology (FCT) [SFRH/BD/122953/2016]
- SYMBIT project - ERDF [CZ.02.1.01/0.0/0.0/15 003/0000477]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/122953/2016] Funding Source: FCT
The clinical applicability of G-quadruplexes (G4s) as anticancer drugs is currently being evaluated. Several G4 ligands and aptamers are undergoing clinical trials following the notable examples of quarfloxin and AS1411, respectively. In this review, we summarize the latest achievements and breakthroughs in the use of G4 nucleic acids as both therapeutic tools ('friends', as healing anticancer drugs) and targets ('foes', within the harmful cancer cell), particularly using aptamers and quadruplex-targeted ligands, respectively. We explore the recent research on synthetic G4 ligands toward the discovery of anticancer therapeutics and their mechanism of action. Additionally, we highlight recent advances in chemical and structural biology that enable the design of specific G4 aptamers to be used as novel anticancer agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据